What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide? 

This is an issue of considerable interest both clinically and for research studies, and the approach to both settings is currently similar: are there any signs or symptoms of ongoing active disease? The key words being “ongoing” and “active”. The expectation once glucocorticoids are started and then...